1.11%
2.05%
-13.86%
-21.97%
19.43%
-17.87%
-21.52%
AI Spotlight on GBT
Company Description
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab.It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.
In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters.Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables.The company was founded in 1926 and is headquartered in Villepinte, France.
Market Data
| Last Price | 27.35 |
| Change Percentage | 1.11% |
| Open | 27.3 |
| Previous Close | 27.05 |
| Market Cap ( Millions) | 345 |
| Volume | 20766 |
| Year High | 40.25 |
| Year Low | 22.1 |
| M A 50 | 26.27 |
| M A 200 | 33.14 |
Financial Ratios
| FCF Yield | 9.13% |
| Dividend Yield | 1.83% |
| ROE | 8.54% |
| Debt / Equity | 103.94% |
| Net Debt / EBIDTA | 331.23% |
| Price To Book | 0.89 |
| Price Earnings Ratio | 10.54 |
| Price To FCF | 10.95 |
| Price To sales | 0.41 |
| EV / EBITDA | 6.44 |
News
- 16:45 - Correction: GUERBET : Financial agenda for 2025
- Jan -13 - Correction: GUERBET : Financial agenda for 2025
- Oct -31 - GUERBET : Financial agenda for 2025
- Oct -24 - GUERBET : Revenue at September 30, 2024.
- Sep -25 - GUERBET : H1 2024 results.
- Jul -25 - GUERBET : H1 2024 revenue.
- Jul -19 - Exploring Undervalued Opportunities on Euronext Paris With Edenred and Two More Stocks
- Jun -21 - Airbus And Two Additional Stocks Estimated To Be Undervalued On Euronext Paris
- May -24 - Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet.
- May -22 - Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics.
- Apr -25 - Guerbet : Q1 2024 revenue.
- Jan -15 - Guerbet: Financial agenda for 2024
- Oct -19 - GUERBET : Revenue at 30 September 2023.
- Oct -12 - Guerbet: CHMP positive opinion
- Sep -20 - Guerbet: 2023 half-year results
- Jul -20 - Guerbet: First-half 2023 revenue
- Jul -17 - Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer
- Jul -10 - Guerbet: Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development
- May -26 - Guerbet: Changes in Guerbet's Board of Directors
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> X-Rays
Expected Growth : 5 %
What the company do ?
Guerbet SA's X-Rays are medical imaging agents used to enhance visibility of internal structures during X-ray procedures, aiding in diagnosis and treatment.
Why we expect these perspectives ?
Guerbet SA's X-Rays segment growth is driven by increasing demand for diagnostic imaging, advancements in digital X-Ray technology, and expanding healthcare infrastructure in emerging markets. Additionally, the company's strategic partnerships and investments in research and development are contributing to its growth.
Segment n°2 -> Magnetic Resonance Imaging
Expected Growth : 6 %
What the company do ?
Magnetic Resonance Imaging (MRI) from Guerbet SA is a non-invasive medical imaging technique using strong magnetic fields and radio waves to produce detailed images of internal body structures.
Why we expect these perspectives ?
Guerbet SA's Magnetic Resonance Imaging segment growth is driven by increasing demand for diagnostic imaging, advancements in MRI technology, and growing adoption in emerging markets. Additionally, the rising prevalence of chronic diseases, such as cancer and neurological disorders, fuels the need for accurate diagnostic tools, contributing to the segment's 6% growth.
Segment n°3 -> Interventional Imaging
Expected Growth : 8 %
What the company do ?
Interventional Imaging from Guerbet SA enables real-time image guidance for minimally invasive procedures, enhancing precision and patient safety.
Why we expect these perspectives ?
Guerbet SA's Interventional Imaging segment growth is driven by increasing demand for minimally invasive procedures, advancements in imaging technologies, and rising adoption of hybrid operating rooms. Additionally, growing incidence of chronic diseases, such as cancer and cardiovascular disease, fuels the need for precise diagnostic imaging, contributing to the segment's 8% growth.
Guerbet Sa Products
| Product Range | What is it ? |
|---|---|
| Diagnostic Imaging | Guerbet SA offers a range of diagnostic imaging products, including contrast agents and injectors, used in medical imaging procedures such as MRI and CT scans. |
| Interventional Imaging | Guerbet SA provides interventional imaging products, including microcatheters and guidewires, used in minimally invasive procedures. |
| Pharmaceuticals | Guerbet SA develops and manufactures pharmaceutical products, including contrast agents and other injectable medications. |
| Medical Devices | Guerbet SA offers a range of medical devices, including injectors and syringes, used in medical imaging and interventional procedures. |
Guerbet SA's Porter Forces
Threat Of Substitutes
Guerbet SA operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the increasing demand for eco-friendly products.
Bargaining Power Of Customers
Guerbet SA has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Guerbet SA relies on a few key suppliers for its raw materials, which gives them some bargaining power. However, the company's long-term contracts and diversified supplier base mitigate this risk.
Threat Of New Entrants
The specialty chemicals industry has high barriers to entry, including significant capital requirements and regulatory hurdles. This makes it difficult for new entrants to compete with established players like Guerbet SA.
Intensity Of Rivalry
The specialty chemicals industry is highly competitive, with several established players competing for market share. Guerbet SA faces intense competition from companies like Croda International and Evonik Industries.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 49.47% |
| Debt Cost | 3.95% |
| Equity Weight | 50.53% |
| Equity Cost | 7.51% |
| WACC | 5.75% |
| Leverage | 97.89% |
Guerbet SA : Quality Control
Guerbet SA passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| INMD | InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and … |
| CEVI.ST | CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the … |
| CHEMM.CO | ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in … |
| EUZ.DE | Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and … |
| ELN.MI | EL.En. S.p.A. engages in the research and development, manufacture, distribution, and sale of laser systems in Europe and internationally. The company offers medical laser equipment for use in the fields … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
EL.En
A-Score
1-Year Total Return ->
🥈
ChemoMetec
A-Score
1-Year Total Return ->
🥉
InMode
A-Score
1-Year Total Return ->
4
Guerbet
A-Score
1-Year Total Return ->
5
CellaVision
A-Score
1-Year Total Return ->
6
